All women should start screening for breast cancer at age 40, with biennial screening continuing through age 74, the U.S. Preventive Services Task Force said in its final recommendation statement April 30.
Northwell Health President & CEO Michael Dowling and Bruce Stillman, President & CEO of Cold Spring Harbor Laboratory. Source: Northwell HealthThe Cold Spring Harbor Laboratory and Northwell Health have renewed their affiliation that was originally announced in 2015.
Miriam Merad was named dean for Translational Research and Therapeutic Innovation of the Icahn School of Medicine at Mount Sinai.
Sana D. Karam will lead radiation oncology at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, beginning Oct. 1.
MD Anderson Cancer Center and the Pan American Health Organization are collaborating to strengthen cancer prevention and control initiatives across the Americas.
The FY24 Defense Appropriations Act provides funding for the Rare Cancers Research Program to support research of exceptional scientific merit in the area of rare cancers research.
Patients in remission after being treated for a high-risk blood cancer are likely to have better outcomes if no trace of the cancer is detectable before the patients receive donor blood cells.
A national study led by researchers at MD Anderson Cancer Center and the University of New Mexico Comprehensive Cancer Center found major gaps in breast, cervical, and colorectal cancer screening use in Federally Qualified Health Centers in the US, relative to overall screening rates in the country.
The phase III KEYNOTE-811 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy met its dual primary endpoint of overall survival for the first-line treatment of patients with human epidermal growth factor receptor 2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Positive high-level results from the DESTINY-Breast06 phase III trial showed that Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy.
